Literature DB >> 16920175

Viral evolution in macaques coinfected with CCR5- and CXCR4-tropic SHIVs in the presence or absence of vaccine-elicited anti-CCR5 SHIV neutralizing antibodies.

Brian Burke1, Nina R Derby, Zane Kraft, Cheryl J Saunders, Chuanbin Dai, Nicholas Llewellyn, Irina Zharkikh, Lucia Vojtech, Tuofu Zhu, Indresh K Srivastava, Susan W Barnett, Leonidas Stamatatos.   

Abstract

Macaques were immunized with SF162 Env-based gp140 immunogens and challenged simultaneously with the CCR5-tropic homologous SHIV(SF162P4) and the CXCR4-tropic heterologous SHIV(SF33A) viruses. Both mock-immunized and immunized animals became dually infected. Prior immunization preferentially reduced the viral replication of the homologous virus during primary infection but the relative replication of the two coinfecting viruses during chronic infection was unaffected by prior immunization, despite the fact that five of six immunized animals maintained a significantly lower overall viral replication that the control animals. Neutralizing antibodies participated in controlling the replication of SHIV(SF162P4), but not that of SHIV(SF33A). Dual infection resulted in the emergence and predominance within the circulating CCR5 virus pool, of a variant with a distinct neutralization phenotype. The signature of this variant was the presence of three amino acid changes in gp120, two of which were located in the receptor and coreceptor binding sites. Also, a significant fraction of the viruses circulating in the blood, as early as two weeks post-infection, was recombinants and prior immunization did not prevent their emergence. These findings provide new insights into the dynamic interaction of CCR5- and CXCR4-tropic HIV isolates that are potentially relevant in better understanding HIV-mediated pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16920175     DOI: 10.1016/j.virol.2006.07.026

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  10 in total

1.  Isolation and characterization of monoclonal antibodies elicited by trimeric HIV-1 Env gp140 protein immunogens.

Authors:  Nina R Derby; Sean Gray; Elizabeth Wayner; Dwayne Campogan; Giorgos Vlahogiannis; Zane Kraft; Susan W Barnett; Indresh K Srivastava; Leonidas Stamatatos
Journal:  Virology       Date:  2007-06-08       Impact factor: 3.616

2.  Characterization of neutralizing antibody responses elicited by clade A envelope immunogens derived from early transmitted viruses.

Authors:  Zane Kraft; Katharine Strouss; William F Sutton; Brad Cleveland; For Yue Tso; Patricia Polacino; Julie Overbaugh; Shiu-Lok Hu; Leonidas Stamatatos
Journal:  J Virol       Date:  2008-04-09       Impact factor: 5.103

3.  HIV-1 Transmission, Replication Fitness and Disease Progression.

Authors:  Tasha Biesinger; Jason T Kimata
Journal:  Virology (Auckl)       Date:  2008-07-14

4.  Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites.

Authors:  Samantha Townsley; Yun Li; Yury Kozyrev; Brad Cleveland; Shiu-Lok Hu
Journal:  J Virol       Date:  2015-10-28       Impact factor: 5.103

5.  Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes.

Authors:  Catherine A Blish; D Noah Sather; George Sellhorn; Leonidas Stamatatos; Yide Sun; Indresh Srivastava; Susan W Barnett; Brad Cleveland; Julie Overbaugh; Shiu-lok Hu
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

6.  Differential pathogenicity of SHIV infection in pig-tailed and rhesus macaques.

Authors:  Patricia Polacino; Kay Larsen; Lindsey Galmin; John Suschak; Zane Kraft; Leonidas Stamatatos; David Anderson; Susan W Barnett; Ranajit Pal; Kristen Bost; A H Bandivdekar; Christopher J Miller; Shiu-Lok Hu
Journal:  J Med Primatol       Date:  2008-12       Impact factor: 0.667

7.  Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses.

Authors:  Yun Li; Bradley Cleveland; Igor Klots; Bruce Travis; Barbra A Richardson; David Anderson; David Montefiori; Patricia Polacino; Shiu-Lok Hu
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103

8.  The first hypervariable region of the gp120 Env glycoprotein defines the neutralizing susceptibility of heterologous human immunodeficiency virus type 1 isolates to neutralizing antibodies elicited by the SF162gp140 immunogen.

Authors:  Lance K Ching; Giorgos Vlachogiannis; Katherine A Bosch; Leonidas Stamatatos
Journal:  J Virol       Date:  2007-11-14       Impact factor: 5.103

9.  Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies.

Authors:  Zane Kraft; Nina R Derby; Ruth A McCaffrey; Rachel Niec; Wendy M Blay; Nancy L Haigwood; Eirini Moysi; Cheryl J Saunders; Terri Wrin; Christos J Petropoulos; M Juliana McElrath; Leonidas Stamatatos
Journal:  J Virol       Date:  2007-03-28       Impact factor: 5.103

10.  Evolution of naturally occurring 5'non-coding region variants of Hepatitis C virus in human populations of the South American region.

Authors:  Gonzalo Moratorio; Mariela Martínez; María F Gutiérrez; Katiuska González; Rodney Colina; Fernando López-Tort; Lilia López; Ricardo Recarey; Alejandro G Schijman; María P Moreno; Laura García-Aguirre; Aura R Manascero; Juan Cristina
Journal:  Virol J       Date:  2007-08-02       Impact factor: 4.099

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.